A PHASE II RANDOMIZED, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF IMCGP100 COMPARED WITH INVESTIGATOR'S CHOICE IN HLA-A*0201 POSITIVE PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED UVEAL MELANOMA

Registry ID

IMCGP100-202

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

IMMUNOCORE LTD.

Start date

2018-04-04

Last update

2017-03-30

Conditions

• UVEAL MELANOMA

Related clinical trials

• A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF NEOADJUVANT DAROVASERTIB IN SUBJECTS WITH PRIMARY NON-METASTATIC UVEAL MELANOMA (OPTIMUM-10)
• IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2)
• (NEO)ADJUVANT IDE196 (DAROVASERTIB) IN PATIENTS WITH LOCALIZED OCULAR MELANOMA
• A PHASE 1/2 STUDY OF IDE196 IN PATIENTS WITH SOLID TUMORS HARBORING GNAQ/11 MUTATIONS OR PRKC FUSIONS
• A PHASE I/II, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF IMCGP100 USING THE INTRA-PATIENT ESCALATION DOSING REGIMEN PATIENTS WITH ADVANCED UVEAL MELANOMA

View on source registry